CSL Limited (ASX:CSL), a constituent of the S&P/ASX 200 and one of the world's largest biotechnology companies, released its FY26 results, reporting underlying NPATA of $3.1 billion, down 2%, and describing the year as one of decisive action and reset. After $7.1 billion in pre-tax impairments in FY26 — relating principally to adverse changes in commercial outlook, generic competition timing, regulatory developments, and site utilisation — CSL reported a statutory net loss of $2.6 billion. The transformation program achieved approximately $176 million in cost savings, ahead of target.

About the Company

CSL Limited is a global biotechnology company with three major Business divisions: CSL Behring (the world's leading plasma-derived medicines and recombinant therapy business), CSL Vifor (iron deficiency and nephrology medicines), and CSL Seqirus (the world's second largest influenza Vaccine manufacturer). CSL's products treat rare and serious medical conditions including immune deficiencies, haemophilia, hereditary angioedema, and iron deficiency anaemia. The company has Manufacturing operations across the US, Australia, Germany, Switzerland, and multiple other countries.

FY26 Results

Total Revenue was $15.8 billion, down 1% in constant currency. Underlying NPATA was $3.1 billion, down 2% in constant currency. Reported net loss after tax was $2.6 billion, after $7.1 billion in total pre-tax impairments (principally Goodwill and intangible assets) recognised in FY26. Cash Flow from operations was $3.5 billion. Transformation program delivered approximately $176 million in cost savings, ahead of target. One-off pre-tax restructuring costs in FY26 were $799 million. CSL Behring total revenue was $11.4 billion, down 1%: Ig sales $6.2 billion (flat), reflecting US Ig channel inventory normalisation and Medicare Part D changes; Albumin $1.1 billion (down 17%), impacted by China government cost containment; Haemophilia $1.5 billion (down 1%), with HEMGENIX up 25% and ANDEMBRY achieving $240 million in its first full year. CSL Vifor total revenue was $2.4 billion, up 3%. CSL Seqirus total revenue was $2.0 billion, down 8%, due to the non-recurring avian influenza outbreak revenue in FY25; global seasonal influenza sales were up 4% and FLUAD sales of $968 million were up 5%. CSL announced approximately $1.5 billion of US plasma manufacturing expansion including the Horizon 2 Yield improvement program. FY27 guidance: return to sustainable growth, with transformation benefits and newer therapies driving top-line growth.

Distribution

CSL maintained its final Dividend at $1.62 per share. No Interim Dividend was paid. The Board determined to continue the existing share buy-back program.

Index Context

CSL is one of the largest companies in the S&P/ASX 200 by Market Capitalisation and is the index's primary large-cap biotechnology and pharmaceutical holding. For S&P/ASX 200 investors, CSL provides unique exposure to global plasma-derived medicines, haemophilia gene therapy (HEMGENIX), hereditary angioedema treatment (ANDEMBRY), influenza vaccines, and nephrology pharmaceuticals — all of which are non-cyclical healthcare products with long-term structural demand. The scale and breadth of CSL's impairments in FY26 reflects both the complexity of its Vifor Acquisition integration and a recalibration of long-term commercial assumptions for several product lines.

Material Risks and Uncertainties

The $7.1 billion in impairments signals that several product and business assumptions have been reset downward — including the timing of generic competition and regulatory risks for certain CSL Vifor products. China's government cost containment on albumin (CSL Behring's albumin sales fell 17%) is an ongoing revenue risk for the world's largest plasma products market. The Horizon 2 US plasma yield improvement program requires FDA and EMA engagement before the clinical evidence can be filed for regulatory approval, introducing regulatory and timeline risk. The $799 million in one-off restructuring costs in FY26 is complete but represents a permanent step down in the asset base.

Upcoming Milestones

The regulatory approval pathway for the Horizon 2 plasma yield improvement program — which requires clinical evidence to be obtained before FDA and EMA filings — is the most important long-term technical milestone for CSL. ANDEMBRY's continued commercial ramp-up in its second full year of market availability (FY27) will be closely watched, as will HEMGENIX's growth trajectory given its position as the world's first approved haemophilia B gene therapy. The US plasma manufacturing expansion Investment of approximately $1.5 billion will build manufacturing capacity that underpins long-term Ig and albumin supply. The FY27 interim result will be the first test of CSL's return to sustainable underlying Earnings growth.